TRIM47: Key Regulator of Immune Response and Cell Death (G91107)

Target Name: TRIM47

NCBI ID: G91107

TRIM47

TRIM47: Key Regulator of Immune Response and Cell Death

TRIM47 (Tumor Necrosis Factor-Inflammasome-associated protein 47) is a protein that is expressed in various tissues of the body, including the lungs, liver, and skeletal muscles. It is a key regulator of the immune response and has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the key functions of TRIM47 is its role in the regulation of inflammation. When the body is exposed to an infection or injury, TRIM47 helps to coordinate the immune response by activating and regulating the activity of immune cells. This includes the activation and proliferation of natural killer cells, which are important for destroying infected or damaged cells.

In addition to its role in inflammation, TRIM47 is also involved in the regulation of cell death and has been implicated in a number of neurodegenerative diseases. For example, studies have suggested that TRIM47 may be involved in the development and progression of Alzheimer's disease, and that it may also contribute to the development of other neurodegenerative disorders.

Another function of TRIM47 is its role in cancer progression. TRIM47 has been shown to be expressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. It has also been shown to play a role in the development of cancer stem cells, which are cells that have the ability to generate new, cancerous cells.

TRIM47 is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and inflammation, and is a key factor in the development and progression of many diseases.

Despite its many functions, TRIM47 is still an relatively well-known protein. There is ongoing research into its potential as a drug target and biomarker, with studies suggesting that it may be a promising target for a variety of conditions, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the key challenges in studying TRIM47 is its complex structure and the difficulty of studying a protein that is expressed in a variety of tissues. However, researchers are working to overcome these challenges by developing new techniques for the study of TRIM47, including mass spectrometry and biochemical assays.

In addition to its potential as a drug target and biomarker, TRIM47 is also of interest to researchers because of its potential role in the development of cancer. Many studies have suggested that TRIM47 may be involved in the development and progression of cancer, and that it may play a role in the development of cancer stem cells.

Overall, TRIM47 is a protein that continues to be of interest to researchers due to its complex role in the regulation of the immune response and cell death. While more research is needed to fully understand its functions and potential as a drug target and biomarker, its potential contributions to the study of a wide range of diseases make it a valuable molecule to study.

Protein Name: Tripartite Motif Containing 47

Functions: E3 ubiquitin-protein ligase that mediates the ubiquitination and proteasomal degradation of CYLD

The "TRIM47 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM47 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets